Cytotoxicity testing of medical pressure-sensitive adhesive tapes is a fundamental biocompatibility requirement for products that contact skin or wounds, ensuring that adhesive leachables do not harm living cells. Performed in accordance with ISO 10993-5 and GB/T 16886.5, this in vitro evaluation is typically the first biological test requested by regulators for adhesive-based medical devices. This article explains the applicable standards, sample preparation, testing methods, acceptance criteria, and practical considerations for manufacturers.
Technical Overview
Medical pressure-sensitive adhesive tapes are widely used for wound closure, device fixation, securement of dressings, surgical draping, and transdermal drug delivery. Because these products maintain direct contact with skin, mucosal membranes, or breached surfaces for durations ranging from minutes to several days, any substance migrating out of the adhesive layer or backing material has the potential to damage cells at the contact site.
Adhesive formulations are chemically complex. They may contain residual monomers, tackifying resins, plasticizers, antioxidants, crosslinking agents, and processing residues, all of which can leach into physiological fluids. Cytotoxicity testing provides a rapid, sensitive, and cost-effective in vitro screening method to detect these leachable hazards before in vivo studies or clinical use are undertaken.
Under ISO 10993-1 (Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process), adhesive tapes used on skin are classified as surface-contacting devices with either limited (up to 24 hours) or prolonged (24 hours to 30 days) contact duration. For both categories, in vitro cytotoxicity is a baseline evaluation endpoint. The specific test methodology is defined in ISO 10993-5, with sample preparation governed by ISO 10993-12. In the Chinese regulatory framework, the equivalent standards are GB/T 16886.5 and GB/T 16886.12.
Testing Samples
Medical Pressure-Sensitive Adhesive Tapes
Sterile and non-sterile fixation tapes, wound tapes, and securement tapes with acrylic, silicone, or rubber-based adhesive systems on woven, nonwoven, film, or foam backings. These constitute the primary sample category for cytotoxicity evaluation.
Wound Dressings with Adhesive Borders
Island dressings, foam dressings, hydrocolloid dressings, and transparent film dressings in which the adhesive border is an integral functional component. The complete product, including both the adhesive mass and the absorbent pad, is typically evaluated.
Surgical and Incise Drapes
Adhesive films and drape edge adhesives applied to intact skin in the surgical field, where the adhesive contacts skin for the duration of the procedure under occlusion.
Transdermal Systems and Electrode Tapes
Transdermal patch components, electrically conductive adhesive electrodes for ECG monitoring, and adhesive tapes used in biosensor fixation, where chemical release from the adhesive may be enhanced by moisture and prolonged wear.
Raw Materials and Components
Adhesive masses, backing films, primers, and release liners submitted during research and development for early-stage material screening, supplier qualification, or comparative formulation studies.
Testing Items
A comprehensive cytotoxicity evaluation program for medical pressure-sensitive adhesive tapes typically includes the following items, selected based on product configuration and regulatory strategy:
- In vitro cytotoxicity by the extract (elution) method — the most widely applied approach for adhesive tapes
- Direct contact cytotoxicity assay — suitable for evaluating surface interactions of solid tape specimens
- Indirect contact cytotoxicity — agar diffusion or filter diffusion assays for materials with diffusible leachables
- Quantitative cell viability determination using MTT tetrazolium reduction, neutral red uptake (NRU), or crystal violet staining
- Qualitative morphological assessment and cytotoxicity grading on the 0 to 4 reactivity scale
- Extract characterization, including visual appearance, pH, and sterility verification of the extraction system
Testing Methods
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12. Test specimens are cut aseptically to a defined size, and the extraction ratio is determined by the material form and thickness. For thin adhesive tapes and films with a thickness below 0.5 mm, a ratio of 6 cm² of total surface area per milliliter of extract is commonly applied; for thicknesses between 0.5 mm and 1 mm, 3 cm²/mL is used. Alternatively, mass-based ratios of 0.1 g/mL to 0.2 g/mL may be applied for irregularly shaped components.
Common extraction vehicles include serum-supplemented Minimum Essential Medium (MEM), physiological saline, and other solvents justified by the nature of the adhesive chemistry. Standard extraction conditions include 37°C for 24 hours to simulate physiological contact, with accelerated conditions such as 50°C for 72 hours or 70°C for 24 hours available to maximize leachable recovery while avoiding material degradation or chemical artifact formation.
Cell System
The mouse connective tissue fibroblast cell line L929 is the preferred and most widely accepted cell system, as recommended by ISO 10993-5 and GB/T 16886.5. Other validated lines, such as BALB/c 3T3 or V79 cells, may also be used where scientifically justified. Cells are seeded to achieve a subconfluent monolayer at the time of dosing, and cultures are verified to be free of mycoplasma contamination.
Exposure Conditions
For the extract method, cells are exposed to the undiluted extract (100%) and serial dilutions (typically 50% and 25%) for 24 to 48 hours. For the direct contact method, sterile tape specimens are placed gently onto the cell monolayer with defined contact area, ensuring minimal mechanical stress. For agar diffusion, specimens are placed over an agar overlay covering the monolayer, allowing diffusion of soluble leachables while preventing physical damage to the cells.
Controls
Each test run includes a negative control, typically high-density polyethylene, which is expected to produce no cytotoxic response. A positive control such as zinc diethyldithiocarbamate (ZDEC) or dilute Triton X-100 solution is included to confirm system sensitivity. Blank extraction medium without test material is used to establish the baseline for quantitative comparison.
Evaluation Criteria
Qualitative evaluation grades cellular response from Grade 0 (no reactivity) to Grade 4 (severe reactivity) based on morphology, cell rounding, detachment, and lysis, examined microscopically. A response not exceeding Grade 2 is generally considered acceptable. For the quantitative MTT or NRU assay, ISO 10993-5 specifies that mean cell viability of 70% or greater relative to the blank control indicates the sample is non-cytotoxic. Results falling below this threshold require dilution-response analysis and a documented scientific justification or material reformulation.
Test Validity and Reporting
The test is valid only when negative and positive controls respond as expected and cells remain within logarithmic growth parameters. The final report documents sample description, extraction parameters, cell line and passage number, viability data with statistical treatment, reactivity grades, photographic evidence, and a conclusion on compliance with the acceptance criteria.
Applications
Cytotoxicity testing of medical pressure-sensitive adhesive tapes supports multiple stages of the product lifecycle and serves diverse regulatory and quality objectives:
- Regulatory submissions for medical device registration in China, the European Union, the United States, and other jurisdictions where ISO 10993 series or GB/T 16886 series compliance is required
- Biocompatibility screening during adhesive formulation development and material selection, enabling rapid comparison of candidate adhesives and backings
- Supplier qualification and incoming raw material verification for adhesive masses, films, and finished tape components
- Change control evaluation when adhesives, backing materials, manufacturing processes, sterilization methods, or packaging are modified
- Support of biological evaluation plans and risk management files under the ISO 10993-1 and ISO 14971 frameworks
- Batch release testing and periodic quality monitoring for high-risk product lines, performed by accredited third-party laboratories or in-house biosafety facilities
- Root cause investigation following field complaints or adverse event reports involving skin reactions
FAQ
Which standard governs cytotoxicity testing of medical adhesive tapes?
The core methodology is defined in ISO 10993-5 (Tests for in vitro cytotoxicity), with sample preparation specified in ISO 10993-12. The Chinese national equivalents are GB/T 16886.5 and GB/T 16886.12. Related methods include ASTM F813 for direct contact evaluation and ASTM F895 for agar diffusion screening.
What is the pass criterion for cytotoxicity testing?
For quantitative assays, mean cell viability of at least 70% relative to the blank control indicates the sample is non-cytotoxic. For qualitative microscopic grading, a reactivity grade of 2 or lower is generally considered acceptable. Results above these thresholds indicate the presence of cytotoxic leachables requiring investigation.
How are adhesive tape samples prepared for extraction?
Samples are cut aseptically and extracted at a surface-area-to-volume ratio based on total material thickness, typically 6 cm²/mL for tapes thinner than 0.5 mm. Extraction is performed in serum-supplemented MEM or saline at 37°C for 24 hours, with alternative accelerated conditions available when justified.
How long does cytotoxicity testing take?
Standard turnaround for the extract method is typically two to four weeks, including cell culture preparation, extraction, exposure, staining, and reporting. Direct contact and agar diffusion assays generally follow a similar timeline. Retesting or dilution series confirmation may extend the schedule.
Is cytotoxicity testing mandatory for skin-contacting tapes?
Yes. Under ISO 10993-1, in vitro cytotoxicity is a foundational endpoint for surface-contacting devices with skin contact under both limited and prolonged exposure categories, and it is requested by essentially all major regulatory authorities as part of the biological evaluation file.
Can a passing cytotoxicity result replace other biocompatibility tests?
No. Cytotoxicity is one component of the overall biological evaluation. Depending on contact nature and duration, additional endpoints such as sensitization, irritation, and intracutaneous reactivity testing are typically required to complete the assessment under the risk management approach defined in ISO 10993-1.
What should be done if a tape fails the cytotoxicity test?
Failure generally indicates cytotoxic leachables from the adhesive system, tackifier, or residual monomers. Manufacturers should perform extraction profiling to identify the causative substance, evaluate alternative adhesives or curing conditions, optimize sterilization residuals, and resubmit reformulated samples for confirmation testing at an accredited third-party laboratory.